Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 4
1973 1
1976 1
1983 1
1985 4
1986 1
1987 1
1988 4
1989 4
1990 3
1991 3
1992 5
1993 5
1994 9
1995 9
1996 6
1997 6
1998 8
1999 10
2000 5
2001 13
2002 12
2003 14
2004 10
2005 22
2006 20
2007 38
2008 42
2009 46
2010 62
2011 79
2012 76
2013 58
2014 67
2015 70
2016 78
2017 82
2018 87
2019 92
2020 77
2021 108
2022 89
2023 96
2024 120
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,370 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: chae ys. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ. Pai SG, et al. Among authors: chae yk. J Hematol Oncol. 2017 May 5;10(1):101. doi: 10.1186/s13045-017-0471-6. J Hematol Oncol. 2017. PMID: 28476164 Free PMC article. Review.
Diversity and complexity of cell death: a historical review.
Park W, Wei S, Kim BS, Kim B, Bae SJ, Chae YC, Ryu D, Ha KT. Park W, et al. Among authors: chae yc. Exp Mol Med. 2023 Aug;55(8):1573-1594. doi: 10.1038/s12276-023-01078-x. Epub 2023 Aug 23. Exp Mol Med. 2023. PMID: 37612413 Free PMC article. Review.
Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA.
Lee YH, Jang HJ, Kim S, Choi SS, Khim KW, Eom HJ, Hyun J, Shin KJ, Chae YC, Kim H, Park J, Park NH, Woo CY, Hong CH, Koh EH, Nam D, Choi JH. Lee YH, et al. Among authors: chae yc. Elife. 2021 Dec 29;10:e70472. doi: 10.7554/eLife.70472. Elife. 2021. PMID: 34964438 Free PMC article.
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
Yamashita T, Sohn JH, Tokunaga E, Niikura N, Park YH, Lee KS, Chae YS, Xu B, Wang X, Im SA, Li W, Lu YS, Aguilar CO, Nishijima S, Nishiyama Y, Sugihara M, Modi S, Tsurutani J. Yamashita T, et al. Among authors: chae ys. Breast Cancer. 2024 Sep;31(5):858-868. doi: 10.1007/s12282-024-01600-7. Epub 2024 Jun 17. Breast Cancer. 2024. PMID: 38884900 Free PMC article. Clinical Trial.
PLCγ1: Potential arbitrator of cancer progression.
Jang HJ, Suh PG, Lee YJ, Shin KJ, Cocco L, Chae YC. Jang HJ, et al. Among authors: chae yc. Adv Biol Regul. 2018 Jan;67:179-189. doi: 10.1016/j.jbior.2017.11.003. Epub 2017 Nov 8. Adv Biol Regul. 2018. PMID: 29174396 Review.
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.
Shen J, Choi YL, Lee T, Kim H, Chae YK, Dulken BW, Bogdan S, Huang M, Fisher GA, Park S, Lee SH, Hwang JE, Chung JH, Kim L, Song H, Pereira S, Shin S, Lim Y, Ahn CH, Kim S, Oum C, Kim S, Park G, Song S, Jung W, Kim S, Bang YJ, Mok TSK, Ali SM, Ock CY. Shen J, et al. Among authors: chae yk. J Immunother Cancer. 2024 Feb 14;12(2):e008339. doi: 10.1136/jitc-2023-008339. J Immunother Cancer. 2024. PMID: 38355279 Free PMC article.
Nodal Signaling as a Developmental Therapeutics Target in Oncology.
Kalyan A, Carneiro BA, Chandra S, Kaplan J, Chae YK, Matsangou M, Hendrix MJC, Giles F. Kalyan A, et al. Among authors: chae yk. Mol Cancer Ther. 2017 May;16(5):787-792. doi: 10.1158/1535-7163.MCT-16-0215. Mol Cancer Ther. 2017. PMID: 28468864 Review.
1,370 results